Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its neurology portfolio with a new licensing agreement for XADAGO (safinamide), an add-on treatment for adult patients with idiopathic Parkinson’s disease licensed by Zambon, an Italian multinational pharmaceutical company committed to innovating cure and care to make patients’ lives better.
The agreement will see Pharmanovia acquire the rights from existing licensee, CSL Seqirus in Australia and New Zealand, with Pharmanovia exclusively responsible for regulatory and commercial activity in the region. Pharmanovia will also become MAH holder.
Parkinson’s is the fastest growing neurological condition in the world according to the World Health Organization.
Pharmanovia CEO, James Burt commented: “Today’s announcement brings us a new chemical entity (NCE), with clear synergies to our existing CNS portfolio. In XADAGO (safinamide) we have an important medicine helping patients to control Parkinson’s symptoms and we’re excited to use our platform to continue to bring this medicine to patients.
“CSL Seqirus’ trust in handing over this product to us, further reinforces our ability as a core commercial partner in Australia and New Zealand, and as a partner more broadly for novel therapeutics”.
Danielle Dowell, CSL Seqirus Executive Director for Commercial Operations APAC, added: “Pharmanovia has strong capabilities and presence both in ANZ and in CNS. They are experienced at bringing differentiated products to patients and we’re confident that they will leverage their portfolio to help reach even more people living with Parkinson’s.”
